

1 **Title:** Sars-Cov-2 antibody titer 3 months post-vaccination is affected by age, gender, smoking
2 and vitamin D.

3 **Short title:** Sars-Cov-2 antibodies after vaccination.

4 Anastasia Parthymou¹, Evagelia E Habeos¹, George I Habeos¹, Apostolos Deligakis², Ektoras
5 Livieratos¹, Markos Marangos³, Dionysios V Chartoumpekis^{1,*}

6 ¹Division of Endocrinology, Department of Internal Medicine, University of Patras, Patras,
7 26504, Greece

8 ² "St Andrews" State General Hospital, Patras, 26335, Greece.

9 ³Division of Infectious Diseases, Department of Internal Medicine, University of Patras, Patras,
10 26504, Greece

11 *Corresponding author: Asklipiou 1 St, School of Medicine, University of Patras, Patras, 26504,
12 Greece. Tel. +302610969130. E-mail. dchart@upatras.gr

13 Keywords: COVID-19, antibodies, DHEAS, 25(OH)D, aged, smokers

14 Disclosure summary: The authors have nothing to disclose

15 ClinicalTrials.gov Identifier: NCT04954651

16

17

18 **Abstract**

19 *Context*

20 Vaccination against Sars-Cov-2 is in full swing during COVID-19 pandemic. One of the efficient
21 methods to evaluate response to vaccination is the assessment of humoral immunity by
22 measuring Sars-Cov-2 antibody titer. Identification of factors that affect the humoral response is
23 important so as to ameliorate the responses to vaccination or identify vulnerable groups that may
24 need vaccination boosters.

25 *Objective*

26 We investigated the effect of anthropometric parameters (age, BMI), smoking, diabetes, statin
27 use hypertension and levels of 25(OH)D and DHEAS to the Sars-Cov-2 antibody titer.

28

29 *Methods*

30 In this longitudinal observational cohort study 712 subjects were tested for Sars-Cov-2
31 antibodies 3 months after the second dose of BNT162b2 vaccine. Multiple linear regression
32 analysis was performed to identify which factors are associated with the antibody titer.

33 *Results*

34 We identified age to be negatively associated with antibody titer ($p=0.0073$) and male sex
35 ($p=0.0008$). However, interaction of age and gender was significant ($p<0.0001$) highlighting the
36 finding that only after the age of 40 years men had lower antibody levels than women. DHEAS,
37 an aging marker, was not associated with the antibody titer. Smoking was also associated with

38 low antibody titer ($p=0.0008$) while overweight or obese subjects did not have different antibody
39 response compared to normal weight individuals. Although diabetic and hypertensive subjects
40 trended towards lower antibody titer, this association was not statistically significant. Replete
41 vitamin D levels were associated with higher antibody titers ($p=0.00422$).

42 *Conclusions*

43 Age, male sex and smoking negatively affects antibody titer while 25(OH)D is associated with
44 increased Sars-Cov-2 antibody titers.

45

46

47

48

49

50 **Introduction**

51 SARS-CoV-2 has spread worldwide since January 2020 resulting by the end of July 2021 to
52 about 197 million confirmed cases of COVID-19 with over 4 million deaths according to World
53 Health Organization. Pharmaceutical and biotechnology companies started developing COVID-
54 19 vaccines and four have received so far authorization to be used in European Union
55 (BioNTech and Pfizer, Moderna, AstraZeneca, Johnson & Johnson/Janssen Pharmaceuticals).
56 BNT162b2 vaccine developed by BioNTech and Pfizer is a lipid nanoparticle-formulated
57 nucleoside-modified RNA encoding the SARS-CoV-2 spike glycoprotein (1) and was the first to
58 receive approval for use in European Union, hence being of the first to be administered in
59 Greece. The safety and 95% efficacy in preventing symptomatic COVID-19 of BNT162b2
60 vaccine had been initially shown by the BioNtech-Pfizer clinical trials(1) and similar results
61 were obtained in other studies(2-5).

62 The humoral immune response to COVID-19 vaccination has usually been assessed in clinical
63 trials by measuring the antibody titer (including IgG) against the SARS-CoV-2 spike (S)
64 protein(6,7). However, FDA and other regulatory bodies do not recommend assessment of
65 immunity after COVID-19 vaccination by measuring antibody titer. Nevertheless, commercial
66 serological assays show over 90% positive agreement for distinguishing neutralizing antibodies
67 at the same neutralizing titer while the negative percent agreement was poorer (less than 80%)
68 (8). Hence, antibody titer against SARS-CoV-2 spike (S) protein can be an easy measure of the
69 humoral immune response to COVID-19 vaccination in the real world.

70 It has been a matter of concern that specific populations will not be able to develop an effective
71 immune response after COVID-19 vaccination. Such groups include but they are not limited to
72 aged individuals, immunocompromised patients due to autoimmune diseases or due to
73 immunosuppressive medication, cancer patients and obese/diabetic patients. Thus, studies with
74 kidney transplant recipients (9), cancer patients(10,11) came into focus. Moreover, the
75 identification of other factors that can possibly impair or boost the immune response is important
76 so as to identify individuals that might be at risk even after COVID-19 vaccination. Such factors
77 can be obesity (12), aging (13), dehydroepiandrosterone sulfate (DHEAS), a steroid that declines
78 with aging (14), vitamin D (15), statin use (16), smoking (17) and hypertension (18).

79 As previous studies on SARS-CoV-2 antibodies response (reviewed in (19)) are limited by
80 number of patients and their methodologies, we report herein the real-world humoral
81 immunogenic response to BNT162b2 vaccine in subjects of western Greece vaccinated against
82 COVID-19, and we assess potential parameters that may affect this response.

83

84 **Methods**

85 *Design, setting and study population*

86 This is a longitudinal observational cohort study (ClinicalTrials.gov Identifier: NCT04954651,
87 approved by the University Hospital of Patras Ethics Committee, approval ID 99-25/2/202) in
88 healthcare units of western Greece. Blood samples were drawn before vaccination, 3 weeks and
89 3 months after the second dose of vaccination with BNT162b2 vaccine (BioNTech and Pfizer) as
90 part of the national COVID-19 vaccination program in Greece. Blood samples at the 3-weeks
91 timepoint were drawn only from a portion of our cohort (**Fig. 1**). Participation was based on
92 informed written consent. All adults of any age and gender were eligible to participate in this
93 study. Data about body weight, height, smoking, diabetes, hypertension and statin use were
94 obtained from all participants based on questionnaires. Exclusion criteria were: past medical
95 history of COVID-19 or infection with SARS-Cov-2 during the study or positive SARS-CoV-2
96 spike (S) protein antibody titer at baseline (before vaccination). Moreover, patients who did not
97 provide all necessary information in the questionnaire or there was not enough sample to run all
98 the assays were excluded from our analyses (**Fig. 1**). As healthcare personnel was prioritized for
99 vaccination in Greece, our cohort consists to a large degree of subjects working at hospitals or
100 health centers.

101 *Laboratory measurements*

102 Serum samples were stored in a -20°C freezer. All serum samples measurements were performed
103 in a Cobas 6000 E601 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) using
104 electrochemiluminescence (ECL) technology for immunoassay analysis. Quantitative
105 determination of antibodies (including IgG) to SARS CoV 2 spike (S) protein receptor binding

106 domain (RBD) was performed using the Elecsys® Anti-SARS-CoV-2 S immunoassay (Roche).
107 Antibody levels higher than 0.8 U/l were considered positive (measurement range 0.4-250 U/ml).
108 Values higher than 250 U/ml were diluted 1:20 to obtain the exact value. 25(OH)D (vitamin D)
109 and DHEAS levels were assessed at the 3-months post-vaccination timepoint. The measuring
110 range for DHEAS is 0.2-1000 µg/dl and for Vitamin D is 3.00-120 ng/mL respectively.

111 *Statistical analysis*

112 Descriptive statistics for baseline characteristics of the study population were calculated as
113 means ± standard deviation (SD). To assess which factors affect the SARS-Cov-2 antibody titer,
114 multiple linear regression modelling was performed with log-transformed antibody titer as a
115 continuous dependent variable and using stepwise entry criteria of $p < 0.05$. Age, sex, smoking,
116 hypertension, diabetes, statin use, body mass index (BMI), DHEAS and Vitamin D were checked
117 for linear association with the log-transformed antibody titer and if no linear association was
118 found for a variable, this variable was converted to categorical using quartiles (DHEAS and
119 vitamin D) or pre-existing categories for BMI (underweight; < 18.5 , normal weight; $18.5-24.9$,
120 overweight; $25-29.9$, obesity; > 30). Participants who did not answer all of the questions from the
121 questionnaire were excluded from the analysis. GraphPad Prism version 9.0.0 for Windows
122 (GraphPad Software, San Diego, CA, USA) was used for all the statistical analyses and graphs
123 generation. **Fig.3** and **Fig.4** graphs were generated using Microsoft Excel 365 (Microsoft,
124 Redmond, WA, USA).

125

126 **Results**

127 *Characteristics of the study sample*

128 Of the 929 participants in the present study, 8 were excluded due to being tested positive for
129 SARS-COV-2 antibodies at baseline or suffered from COVID-19 during the study (**Fig.1**). 209
130 participants were also excluded because at least one parameter in the questionnaire was not
131 answered (for instance not giving information about their age, their body weight etc) or due to
132 technical reasons (not enough sample to run the assay). The serum of the remaining 712
133 participants was assayed for SARS-COV-2 antibodies, DHEAS and vitamin D, 3 months post-
134 vaccination. 198 of them were also tested for SARS-COV-2 antibodies 3 weeks after the second
135 dose of the vaccine (**Fig. 1**). The baseline characteristics (gender, age, BMI, smoking, diabetes,
136 hypertension, use of statins) of our study population (n=712) can be seen in **Table 1**.

137

138 *SARS-COV-2 antibodies decline from 3 weeks to 3 months post-vaccination*

139 Paired serum samples from a part of cohort (n=198) were tested at 3 weeks as well as 3 months
140 post-vaccination with the second dose of BNT162b2 vaccine. The SARS-COV-2 antibodies
141 levels were assessed at both of these timepoints. Pairing was significantly effective (correlation
142 coefficient $r=0.8139$, $p<0.0001$) and paired t-test showed that the log antibody titer significantly
143 declines with time (mean of differences between 3 months and 3 weeks is -0.23 ± 0.34
144 ($p<0.0001$) (**Fig. 2**).

145

146

147 *Multiple linear regression analysis of the effect of various factors on SARS-COV-2 antibody titer*

148 To examine which factors can potentially affect the SARS-COV-2 antibody titer in our cohort 3
149 months post-vaccination, we employed a multiple linear regression analysis model, including
150 initially all considered parameters (gender, age, smoking, hypertension, hypertension, diabetes,
151 statin use, BMI, vitamin D and DHEAS levels). As BMI, DHEAS and vitamin D levels did not
152 show linear association with the antibody titer, these variables were converted to categorical ones
153 using quartiles for DHEAS and Vitamin D, and the categories of underweight, normal weight,
154 overweight and obese in the case of BMI. The results of the multiple linear regression analysis
155 model that incorporates all these factors can be seen in **Table 2**. Using step-wise entry criteria
156 with $p < 0.05$, the parameters diabetes, hypertension, prior statin use, BMI and DHEAs were
157 excluded one by one with the aforementioned order rebuilding each time the linear regression
158 model. Finally, the parameters that were found to affect significantly the antibody titer were age,
159 gender, smoking and vitamin D levels (**Table 3**).

160 *Influence of age and gender on SARS-COV-2 antibody titer 3 months post-vaccination*

161 Multivariate linear regression analysis highlighted a statistically significant decreased response
162 of the antibody titer with increasing age (**Table 3, Fig.3**). Male gender also appears to have a
163 negative effect on the antibody titer (**Table 3**). As it is shown in **Fig. 3** male subjects tend to
164 have lower antibody titer compared to female after the age of 40. Indeed, the effect of gender on
165 antibody titer is modified by age as the interaction of sex and age is significant ($p < 0.0001$, **Table**
166 **3**).

167 Since DHEAS has been reported as an aging marker with its concentration negatively correlated
168 with age, we hypothesized that DHEAS levels might predict SARS-COV-2 antibody titers.

169 Indeed, in our cohort we confirmed the known negative association between age and DHEAS
170 level (Spearman's $r=-0.46$, $p<0.0001$, **Fig. 4**) but multivariate linear regression analysis did not
171 find DHEAS to be a significant predictor of antibody titer.

172

173 *Metabolic parameters and SARS-COV-2 antibody response 3 months post-vaccination*

174 The metabolic profile of our cohort included information from questionnaires about BMI, history
175 of hypertension or use of antihypertensive drugs, history of diabetes and use of statins.

176 Overweight and obese individuals did not show any different antibody response to vaccination
177 compared to normal weight subjects (**Fig. 5, Table 2**). Even though individuals with diabetes or
178 hypertension tended to have lower levels of antibodies (**Fig. 6** and **Fig.7** respectively)
179 multivariate linear regression analysis showed that these variables do not affect antibody titer
180 independently (**Table 2**). Users of statin treatment were not found to have different antibody
181 response compared to non-users (**Table 2**).

182 *Smokers showed a blunted humoral response to vaccination*

183 In our cohort 245 out of 712 subjects (34.4%) were smokers. Multivariate linear regression
184 analysis revealed a negative association between smoking and antibody titer (95% CI -0.1737 to
185 -0.04567, $p=0.0008$, **Table 3**). The mean antibody titer of smokers 988 ± 781.4 versus
186 731.2 ± 603.9 in non-smokers (**Fig. 8**).

187 *Vitamin D status and humoral response to vaccination*

188 The association of vitamin D and antibody titer was not linear and thus quartiles (Q4; 4.1-18.89,
189 Q3; 18.9-25.67, Q2; 25.68-32.99 Q1; 33-69.8 ng/ml) of vitamin D levels were used instead in the

190 multivariate linear regression model. Q1, Q2 and Q3 quartiles were compared to Q4. A
191 statistically significant association was found between vitamin D levels and antibody response
192 (p=0.0422, **Table 3**). Specifically, individuals with vitamin D levels in the Q2 quartile showed a
193 positive association with antibody titer (95% CI 0.03724 to 0.2091, p=0.0050) while Q1 and Q3
194 quartiles trended to have positive association (**Fig.9, Table 3**).

195

196 Discussion

197 In the present work the potential association of SARS-COV-2 antibody titers after vaccination in
198 volunteers consisting mainly of healthcare workers, was tested with a variety of potential
199 parameters. Age was found to be negatively associated with the antibody titers and men over 40
200 years old maintained lower antibodies titers than women of the same age (**Fig. 3**). Aging has
201 long been considered a factor that affects immunity (20) and has been recognized as an important
202 factor in the current coronavirus pandemic (21). Aged individuals have shown higher mortality
203 rates from COVID-19 (22). The lower antibody titer of aged subjects after vaccination may
204 suggest an impaired immune response and it can be a matter of consideration for providing the
205 aged population with booster shots. Another interesting finding is that males appear to have
206 lower antibody levels but this effect is age-dependent and it is more obvious after the age of 40
207 (**Fig. 3**). This finding is in accordance with another study (23) that used a smaller number of
208 subjects but assessed antibody levels in various timepoints from day 1 to day 50 post-
209 vaccination. It is shown that octogenarians generate much less antibodies and that females older
210 than 80 years old show higher titers. Other major studies detected a correlation of lower antibody
211 concentrations after vaccination with male sex and older age (24,25). It is also noteworthy that
212 age is negatively associated with antibody titer after Sars-Cov-2 infection (26). As men also
213 appear to dominate in COVID-19 case fatality at least in some countries (reviewed in (27)), such
214 findings warrant further investigation with focus on the mechanisms male gender and aging can
215 have such effects on immune response and COVID-19 outcomes.

216 In our cohort the prevalence of smokers was relatively high, i.e. 245/712 (34.4%). Smoking was
217 also concluded to be associated with lower antibody titer after vaccination (**Fig.8 , Table 2**). This
218 finding is in agreement with a recent smaller Italian study (28) and with a larger Japanese study

219 (25) examining the antibody response after COVID-19 vaccination. A meta-analysis of 19
220 clinical studies revealed that smokers have higher odds of COVID-19 disease progression
221 compared to non-smokers (29) indicating that smoking is associated with probably impaired
222 immune response to Sars-Cov-2 or that comorbidities associated with smoking can lead to such a
223 result. The effects of cigarette smoking to immunity has been studied through the years and is
224 usually associated with immunosuppression (30). Hence, health policies aiming to reduce the
225 smoking population should be more thoroughly implemented not only for the cancer prevention
226 and cardiovascular benefits but also for the amelioration in immune responses.

227 Obesity has been officially recognized as a disease in some countries (for instance, by the
228 American Medical Association) as it is a recognized risk factor of cardiovascular disease (31),
229 cancer (32), diabetes, hypertension, dyslipidemia and other comorbidities (33). During the
230 current coronavirus pandemic, obesity has been recognized as a risk factor for greater COVID-19
231 severity (34). In our study the simple index of BMI was calculated based on information
232 provided by the participants. Analysis showed that BMI was not associated with the total
233 antibody titer (**Fig.5, Table 2**). This is in accordance with other studies (24,28). However,
234 another index of central obesity, waist circumference, has been found to be inversely associated
235 with antibody titer (28). Our study is limited by the fact that body weight and height were not
236 measured but they were based on self-reporting of the participants. Diabetes (**Fig.6, Table 2**) and
237 hypertension (**Fig. 7, Table 2**) did not also appear to have an effect on the antibody titer in the
238 present study. Again, the presence of diabetes was not based on HbA1C or on a glucose
239 measurement but only on the reporting of antidiabetic medications. No index of poorly or well-
240 controlled diabetes was used, just the presence or absence of diabetes was recorded based on the
241 medications received. Similarly, hypertension was recorded in the same manner. Metanalyses

242 have shown that diabetes increases the risk for severe COVID-19 (35,36) while reports for
243 hypertension have been more controversial (37) as they have not corrected for potential
244 cofounders such as cardiovascular disease. A recent study (24) showed a negative association
245 between antibody titers and hypertension or diabetes. However, this is not the case in our study
246 where we show no association. This discrepancy could be attributed to differences in the size,
247 age and self-reporting of the populations. Further studies are warranted with more objective
248 evaluation not only of the presence or absence of diabetes or hypertension but also with
249 evaluation of indexes of poor or well management (e.g., HbA1C, measurement of blood pressure
250 on-site etc.).

251 In our cohort among the variables tested was the prior use of statins. Statin use was considered as
252 a potential determinant of antibody response based on previous knowledge of pleiotropic effect
253 of statins on humoral immunity after vaccination (16). Moreover, use of statins in hospitalized
254 COVID-19 patients has been reported to be associated with reduced mortality (38). A
255 meta-analysis also supported this notion (39) but concluded that more and especially prospective
256 studies are needed. With reference to the effect of statins on the humoral response, a report on
257 influenza vaccination focusing mainly in old population showed that chronic statin use had an
258 immunosuppressive effect (16). In our study, statins had no significant effect on the antibody
259 levels post-vaccination (**Table 2**) but it should be noted that only 15.2 % of our cohort used
260 statins (**Table 1**).

261 Besides the anthropometric measurements and past medical history based on the questionnaires,
262 25(OH)D and DHEAS levels were assessed in the subjects of our study. These hormones were
263 selected for different reasons. DHEAS is an aging marker (40) and has been indirectly implicated
264 in immune responses (41). Although we confirmed in our series the negative association of

265 DHEAS levels with age (**Fig. 4**), we could not find any association of DHEAS with the antibody
266 levels (**Table 2**). This means that the negative effect of age on antibody titers is not dependent on
267 DHEAS levels and other mechanisms should be investigated.

268 Vitamin D has been in the spotlight of research for its pleiotropic actions besides bone effects for
269 at least the last 2 decades (15). Its effects on immune response (42) attracted our attention as they
270 may affect the antibody titers after COVID-19 vaccination. Specifically, vitamin D
271 supplementation has been shown to increase antibodies production after influenza vaccination in
272 an elderly population (43) whereas vitamin D deficiency did not have any association with the
273 immunogenic response to influenza vaccination according to a metanalysis (44). Another study
274 did not find any effect of vitamin D levels on post-vaccination antibodies against influenza (45).
275 Herein, subjects with vitamin D levels in the range of 25.68-32.99 ng/ml had a positive
276 association with higher antibody titers when compared with subjects in the lower range of
277 vitamin D in our population (4.1-18.89 ng/ml). The other 2 quartiles of vitamin D 18.9-25.67 and
278 33-69.8 did not show a statistically significant association with higher antibody titers but only a
279 trend as seen in **Fig. 9**. In our study no information was available on whether our subjects were
280 taking vitamin D supplementation and for how long. We just recorded vitamin D levels at a
281 particular timepoint. Thus, it was not possible to know how long these levels were sustained and
282 if there were previous fluctuations. The role of vitamin D in the antibody response after
283 vaccination has not been systematically examined but future studies are warranted. It is worth
284 mentioning that vitamin D supplementation has been tested even in hospitalized COVID-19
285 patients without definitive answers (46).

286 In conclusion, in the present study of 712 individuals we show that the antibody titer generated
287 after 3 months from the last dose of COVID-19 vaccination is negatively associated with age,

288 smoking and male gender after the age of 40 years. No association was found between antibody
289 titer and obesity, diabetes, hypertension or use of statins. DHEAS levels were negatively
290 correlated with age but did not appear to have any effect on the antibody titer. Vitamin D levels
291 showed a positive association with antibodies titer. Moreover, by measuring the antibody titer in
292 198 of our subjects 3 weeks post-vaccination we concluded that there is a decline in the titer
293 between 3 weeks and 3 months. Limitations of our study include the reliance on questionnaire
294 for anthropometric measurements and the reporting of diabetes and hypertension. The final
295 multiple linear regression model that was generated has an adjusted $r^2=0.14$ (**Table 3**), meaning
296 that this model explains roughly only 14% of the variance in our data and indicates that other
297 parameters, besides the ones already taken into consideration, should be included so as to further
298 improve the model. Advantages of our study include the relatively high number of participants,
299 the strict criterion of excluding all subjects that at least one parameter (of those examined) is
300 missing, the use of a multiple linear regression model taking into account all parameters
301 examined in parallel. Last but not least, to the best of our knowledge, this was the first study to
302 examine DHEAS and 25(OH)D levels as potential modulators of the SARS-COV-2 antibody
303 titer response post-vaccination.

304

305

306

307

308 **Acknowledgments**

309 This study was funded by internal funds of Division of Endocrinology, University of Patras. We
310 express our gratitude to Roche Diagnostics (Hellas) for donating the kits for quantitative
311 determination of antibodies (including IgG) to SARS CoV 2 spike (S) protein receptor binding
312 domain (RBD).

313 **Additional Information**

314 *Disclosure summary:* The authors declare no conflicts of interests.

315 **Data availability**

316 Some or all data sets generated during and/or analyzed during the current study are not publicly
317 available but are available from the corresponding author upon reasonable request.

318

319

320 **References**

321

- 322 1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez
323 Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li
324 P, Kalina WV, Cooper D, Frenck RW, Jr., Hammitt LL, Tureci O, Nell H, Schaefer A,
325 Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, Group
326 CCT. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.*
327 2020;383(27):2603-2615.
- 328 2. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J,
329 Gillson N, Atti A, Islam J, Karagiannis I, Munro K, Khawam J, Chand MA, Brown CS,
330 Ramsay M, Lopez-Bernal J, Hopkins S, Group SS. COVID-19 vaccine coverage in
331 health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against
332 infection (SIREN): a prospective, multicentre, cohort study. *Lancet.*
333 2021;397(10286):1725-1735.
- 334 3. Benenson S, Oster Y, Cohen MJ, Nir-Paz R. BNT162b2 mRNA Covid-19 Vaccine
335 Effectiveness among Health Care Workers. *N Engl J Med.* 2021;384(18):1775-1777.
- 336 4. Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, Weil C, Goldshtein I,
337 Twig G, Cohen D, Muhsen K. The effectiveness of the TWO-DOSE BNT162b2 vaccine:
338 analysis of real-world data. *Clin Infect Dis.* 2021.
- 339 5. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M,
340 Reis B, Balicer RD. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
341 Vaccination Setting. *N Engl J Med.* 2021;384(15):1412-1423.

- 342 6. Manisty C, Otter AD, Treibel TA, McKnight A, Altmann DM, Brooks T, Noursadeghi
343 M, Boyton RJ, Semper A, Moon JC. Antibody response to first BNT162b2 dose in
344 previously SARS-CoV-2-infected individuals. *Lancet*. 2021;397(10279):1057-1058.
- 345 7. Salvagno GL, Henry BM, Pighi L, De Nitto S, Gianfilippi GL, Lippi G. Three-month
346 analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in
347 healthcare workers. *J Infect*. 2021;83(2):e4-e5.
- 348 8. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, Diamond MS,
349 Gronowski AM, Farnsworth CW. Association between SARS-CoV-2 Neutralizing
350 Antibodies and Commercial Serological Assays. *Clin Chem*. 2020;66(12):1538-1547.
- 351 9. Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M,
352 Katchman E, Halperin T, Turner D, Goykhman Y, Shibolet O, Levy S, Houry I, Baruch
353 R, Katchman H. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine
354 in kidney transplant recipients without prior exposure to the virus. *Am J Transplant*.
355 2021;21(8):2719-2726.
- 356 10. Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V,
357 Dietrich PY, Taylor BS, Simand PF, Patel D, Wang J, Labidi-Galy I, Fertani S, Leach RJ,
358 Sandoval J, Mesa R, Lathrop K, Mach N, Shah DP. Immunogenicity of SARS-CoV-2
359 messenger RNA vaccines in patients with cancer. *Cancer Cell*. 2021;39(8):1091-1098
360 e1092.
- 361 11. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A,
362 Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A, Reiter Y, Almog R,
363 Halberthal M, Ben-Aharon I. Serologic Status and Toxic Effects of the SARS-CoV-2
364 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. *JAMA Oncol*. 2021.

- 365 12. Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune
366 response to vaccination. *Vaccine*. 2015;33(36):4422-4429.
- 367 13. Frasca D, Blomberg BB. Aging affects human B cell responses. *J Clin Immunol*.
368 2011;31(3):430-435.
- 369 14. Samaras N, Samaras D, Frangos E, Forster A, Philippe J. A review of age-related
370 dehydroepiandrosterone decline and its association with well-known geriatric syndromes:
371 is treatment beneficial? *Rejuvenation Res*. 2013;16(4):285-294.
- 372 15. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism,
373 Molecular Mechanism of Action, and Pleiotropic Effects. *Physiol Rev*. 2016;96(1):365-
374 408.
- 375 16. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of Statins on Influenza
376 Vaccine Response in Elderly Individuals. *J Infect Dis*. 2016;213(8):1224-1228.
- 377 17. Zuo L, He F, Sergakis GG, Koozehchian MS, Stimpfl JN, Rong Y, Diaz PT, Best TM.
378 Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD
379 and corresponding treatments. *Am J Physiol Lung Cell Mol Physiol*. 2014;307(3):L205-
380 218.
- 381 18. Harrison DG, Vinh A, Lob H, Madhur MS. Role of the adaptive immune system in
382 hypertension. *Curr Opin Pharmacol*. 2010;10(2):203-207.
- 383 19. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA,
384 Mackey K. Antibody Response After SARS-CoV-2 Infection and Implications for
385 Immunity : A Rapid Living Review. *Ann Intern Med*. 2021;174(6):811-821.
- 386 20. Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune
387 system. *Nat Immunol*. 2018;19(1):10-19.

- 388 21. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and
389 COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?
390 *Front Physiol.* 2020;11:571416.
- 391 22. Bonanad C, Garcia-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-Gonzalez V,
392 Facila L, Ariza A, Nunez J, Cordero A. The Effect of Age on Mortality in Patients With
393 COVID-19: A Meta-Analysis With 611,583 Subjects. *J Am Med Dir Assoc.*
394 2020;21(7):915-918.
- 395 23. Terpos E, Trougakos IP, Apostolakou F, Charitaki I, Sklirou AD, Mavrianou N,
396 Papanagnou ED, Liacos CI, Gumeni S, Rentziou G, Korompoki E, Papassotiriou I,
397 Dimopoulos MA. Age-dependent and gender-dependent antibody responses against
398 SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2
399 mRNA vaccine. *Am J Hematol.* 2021;96(7):E257-E259.
- 400 24. Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, Indenbaum V,
401 Mandelboim M, Doolman R, Amit S, Mendelson E, Ziv A, Huppert A, Rubin C,
402 Freedman L, Kreiss Y. BNT162b2 COVID-19 vaccine and correlates of humoral immune
403 responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-
404 care workers. *Lancet Respir Med.* 2021.
- 405 25. Kageyama T, Ikeda K, Tanaka S, Taniguchi T, Igari H, Onouchi Y, Kaneda A,
406 Matsushita K, Hanaoka H, Nakada TA, Ohtori S, Yoshino I, Matsubara H, Nakayama T,
407 Yokote K, Nakajima H. Antibody responses to BNT162b2 mRNA COVID-19 vaccine
408 and their predictors among healthcare workers in a tertiary referral hospital in Japan. *Clin*
409 *Microbiol Infect.* 2021.

- 410 26. Yang HS, Costa V, Racine-Brzostek SE, Acker KP, Yee J, Chen Z, Karbaschi M, Zuk R,
411 Rand S, Sukhu A, Klasse PJ, Cushing MM, Chadburn A, Zhao Z. Association of Age
412 With SARS-CoV-2 Antibody Response. *JAMA Netw Open*. 2021;4(3):e214302.
- 413 27. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and
414 gender on COVID-19 outcomes in Europe. *Biol Sex Differ*. 2020;11(1):29.
- 415 28. Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, Caputi A, Rossetti R,
416 Spoltore ME, Filippi V, Gangitano E, Manfrini S, Mariani S, Lubrano C, Lenzi A,
417 Mastroianni C, Gnessi L. Central obesity, smoking habit, and hypertension are associated
418 with lower antibody titres in response to COVID-19 mRNA vaccine. *Diabetes Metab Res*
419 *Rev*. 2021:e3465.
- 420 29. Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A
421 Meta-analysis. *Nicotine Tob Res*. 2020;22(9):1653-1656.
- 422 30. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. *Inflamm Res*.
423 2008;57(11):497-503.
- 424 31. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. *J Clin Endocrinol*
425 *Metab*. 2004;89(6):2595-2600.
- 426 32. Arnold M, Leitzmann M, Freisling H, Bray F, Romieu I, Renehan A, Soerjomataram I.
427 Obesity and cancer: An update of the global impact. *Cancer Epidemiol*. 2016;41:8-15.
- 428 33. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS.
429 Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *JAMA*.
430 2003;289(1):76-79.

- 431 34. Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, Chen YP, Targher G, Byrne
432 CD, George J, Zheng MH. Obesity Is a Risk Factor for Greater COVID-19 Severity.
433 *Diabetes Care*. 2020;43(7):e72-e74.
- 434 35. Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19:
435 a meta-analysis. *Acta Diabetol*. 2021;58(2):139-144.
- 436 36. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, Khare S, Srivastava A.
437 Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-
438 analysis. *Diabetes Metab Syndr*. 2020;14(4):535-545.
- 439 37. Leiva Sisniegues CE, Espeche WG, Salazar MR. Arterial hypertension and the risk of
440 severity and mortality of COVID-19. *Eur Respir J*. 2020;55(6).
- 441 38. Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen MM, Yang H, Bai
442 L, Song X, Lin L, Xia M, Zhou F, Zhou J, She ZG, Zhu L, Ma X, Xu Q, Ye P, Chen G,
443 Liu L, Mao W, Yan Y, Xiao B, Lu Z, Peng G, Liu M, Yang J, Yang L, Zhang C, Lu H,
444 Xia X, Wang D, Liao X, Wei X, Zhang BH, Zhang X, Yang J, Zhao GN, Zhang P, Liu
445 PP, Loomba R, Ji YX, Xia J, Wang Y, Cai J, Guo J, Li H. In-Hospital Use of Statins Is
446 Associated with a Reduced Risk of Mortality among Individuals with COVID-19. *Cell*
447 *Metab*. 2020;32(2):176-187 e174.
- 448 39. Kow CS, Hasan SS. Meta-analysis of Effect of Statins in Patients with COVID-19. *Am J*
449 *Cardiol*. 2020;134:153-155.
- 450 40. Urbanski HF, Mattison JA, Roth GS, Ingram DK. Dehydroepiandrosterone sulfate
451 (DHEAS) as an endocrine marker of aging in calorie restriction studies. *Exp Gerontol*.
452 2013;48(10):1136-1139.

- 453 41. Hazeldine J, Arlt W, Lord JM. Dehydroepiandrosterone as a regulator of immune cell
454 function. *J Steroid Biochem Mol Biol*. 2010;120(2-3):127-136.
- 455 42. Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health and
456 Disease. *Nutrients*. 2020;12(7).
- 457 43. Goncalves-Mendes N, Talvas J, Duale C, Guttman A, Corbin V, Marceau G, Sapin V,
458 Brachet P, Evrard B, Laurichesse H, Vasson MP. Impact of Vitamin D Supplementation
459 on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A
460 Randomized Placebo-Controlled Trial. *Front Immunol*. 2019;10:65.
- 461 44. Lee MD, Lin CH, Lei WT, Chang HY, Lee HC, Yeung CY, Chiu NC, Chi H, Liu JM,
462 Hsu RJ, Cheng YJ, Yeh TL, Lin CY. Does Vitamin D Deficiency Affect the
463 Immunogenic Responses to Influenza Vaccination? A Systematic Review and Meta-
464 Analysis. *Nutrients*. 2018;10(4).
- 465 45. Lee RU, Won SH, Hansen C, Crum-Cianflone NF. 25-hydroxyvitamin D, influenza
466 vaccine response and healthcare encounters among a young adult population. *PLoS One*.
467 2018;13(2):e0192479.
- 468 46. Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C,
469 Meybohm P, Becker M, Skoetz N, Stegemann M, Piechotta V. Vitamin D
470 supplementation for the treatment of COVID-19: a living systematic review. *Cochrane*
471 *Database Syst Rev*. 2021;5:CD015043.

472

473 **Figure legends**

474 **Figure 1.** Study profile. “Post-vaccination” means after the second dose of the BNT162b2
475 vaccine. Missing data means that patients did not provide all necessary information in the
476 questionnaire or there was not enough sample to run all the assays.

477 **Figure 2.** SARS-COV-2 antibody titer from 3 weeks to 3 months post-vaccination with
478 BNT162b2. Dots indicate individual values (n=198) and straight line indicates means of log
479 antibody titer. *p<0.0001, paired t-test.

480 **Figure 3.** SARS-COV-2 antibody titer at 3 months post-vaccination plotted against age (n=712).
481 Spearman’s $r=-0.247$, $p<0.0001$. Red dots indicate female gender and blue dots male gender.

482 **Figure 4.** DHEAS levels plotted against age at 3 months post-vaccination. Spearman’s $r=-0.46$,
483 $p<0.0001$

484 **Figure 5.** SARS-COV-2 antibody titer in underweight (BMI<18.5), normal weight (BM=18.5-
485 24.9), overweight (BMI=25-29.9) and obese (BMI>30) subjects at 3 months post-vaccination.
486 Individual values are depicted with the straight line indicating the means.

487 **Figure 6.** SARS-COV-2 antibody titer in diabetic and non-diabetic subjects at 3 months post-
488 vaccination. The presence of diabetes was based on the reported treatment of diabetes medication
489 by the subjects in the questionnaires. Individual values are depicted with the straight line
490 indicating the means.


491 **Figure 7.** SARS-COV-2 antibody titer in hypertensive and non-hypertensive subjects at 3
492 months post-vaccination. The presence of hypertension was based on the reported treatment of

493 antihypertensive medication by the subjects in the questionnaires. Individual values are depicted
494 with the straight line indicating the means.

495 **Figure 8.** SARS-COV-2 antibody titer in smokers and non-smokers subjects at 3 months post-
496 vaccination. Individual values are depicted with the straight line indicating the means. Multiple
497 linear regression analysis showed statistically significant negative association ($p=0.0008$)

498 **Figure 9.** SARS-COV-2 antibody titer in subjects with different levels of vitamin D. Individual
499 values are depicted with the straight line indicating the means. Multiple linear regression analysis
500 showed statistically significant positive association with statistically significant effect on the
501 vitamin D levels range 25.68-32.99 ng/ml compared to 4.1-18.89 ng/ml.


502



503

504 *Figure 1 Study profile. "Post-vaccination" means after the second dose of the BNT162b2 vaccine. Missing data means that*
505 *patients did not provide all necessary information in the questionnaire or there was not enough sample to run all the assays.*


506



507

508 *Figure 2 SARS-COV-2 antibody titer from 3 weeks to 3 months post-vaccination with BNT162b2. Dots indicate individual values*
509 *(n=198) and straight line indicates means of log antibody titer. *p<0.0001, paired t-test.*

510



511

512 *Figure 3 SARS-COV-2 antibody titer at 3 months post-vaccination plotted against age (n=712). Spearman's $r=-0.247$, $p<0.0001$.*
513 *Red dots indicate female gender and blue dots male gender.*

514

515

516

517

518

519

520


521

522

523

524


525



526

527 *Figure 4 DHEAS levels plotted against age at 3 months post-vaccination. Spearman's $r=-0.46$, $p<0.0001$*


528



529

530 *Figure 5 SARS-COV-2 antibody titer in underweight (BMI<18.5), normal weight (BM=18.5-24.9), overweight (BMI=25-29.9) and*
531 *obese (BMI>30) subjects at 3 months post-vaccination. Individual values are depicted with the straight line indicating the means.*


532



533

534 *Figure 6 SARS-COV-2 antibody titer in diabetic and non-diabetic subjects at 3 months post-vaccination. The presence of diabetes*
535 *was based on the reported treatment of diabetes medication by the subjects in the questionnaires. Individual values are*
536 *depicted with the straight line indicating the means.*

537



538


539 *Figure 7 SARS-COV-2 antibody titer in hypertensive and non-hypertensive subjects at 3 months post-vaccination. The presence of*
540 *hypertension was based on the reported treatment of antihypertensive medication by the subjects in the questionnaires.*

541 *Individual values are depicted with the straight line indicating the means.*

542

543

544



545

546 *Figure 8 SARS-COV-2 antibody titer in smokers and non-smokers subjects at 3 months post-vaccination. Individual values are*
547 *depicted with the straight line indicating the means. Multiple linear regression analysis showed statistically significant negative*
548 *association ($p=0.0008$)*

549

550

551

552

553

554

555

556

557


558

559

560

561

562



563

564 *Figure 9 SARS-COV-2 antibody titer in subjects with different levels of vitamin D. Individual values are depicted with the straight*
565 *line indicating the means. Multiple linear regression analysis showed statistically significant positive association with statistically*
566 *significant effect on the vitamin D levels range 25.68-32.99 ng/ml compared to 4.1-18.89 ng/ml.*

567

568

569

570 **Table 1.** Baseline characteristics of the study population.

Whole study population	n=712
Male	268 (37.6%)
Female	444 (62.4%)
Age (years)	50.8 ± 11.4
BMI (kg/m ²)	26.7 ± 4.9
Smokers	245 (34.4%)
Diabetes	50 (7%)
Hypertension	115 (16.2%)
Statin use	108 (15.2 %)

571 Data show means ± SD

572

573

574

575 **Table 2.** Initial multivariable linear regression model for SARS-COV-2 antibodies titer

Variable	Beta (95% CI)	p-value
Gender (male)	-0.1041 (-0.1747 to -0.0335)	0.0039
Age	-0.01300 (-0.0164 to -0.0096)	<0.0001
Smoking (yes)	-0.1006 (-0.1653 to -0.03599)	0.0023
Hypertension (yes)	-0.04540 (-0.1364 to 0.04560)	0.3276
Diabetes (yes)	-0.01871(-0.1433 to 0.1059)	0.7681
Statin (yes)	0.06516 (-0.02489 to 0.1552)	0.1559
BMI (underweight)	-0.1507 (-0.4253 to 0.1239)	0.2816
BMI (overweight)	0.08446 (0.01126 to 0.1577)	0.0238
BMI (obese)	0.06558 (-0.01823 to 0.1494)	0.1249
DHEAS (Q3)	-0.03468 (-0.1218 to 0.05248)	0.4350
DHEAS (Q2)	-0.03305 (-0.1244 to 0.05827)	0.4776
DHEAS (Q1)	-0.1229 (-0.2226 to -0.02312)	0.0158
25(OH)D (Q3)	0.08445 (-0.001423 to 0.1703)	0.0539
25(OH)D (Q2)	0.1396 (0.05289 to 0.2262)	0.0016
25(OH)D (Q1)	0.1158 (0.02801 to 0.2035)	0.0098

576 25(OH)D quartiles: Q4; 4.1-18.89, Q3; 18.9-25.67, Q2; 25.68-32.99 Q1; 33-69.8 ng/ml

577 DHEAS quartiles: Q4; 0.3-89.59, Q3; 89.6-145.9, Q2; 146-217.39, Q1; 217.4-637.6 µg/dl

578

579 **Table 3.** Final multivariable linear regression model for SARS-COV-2 antibodies titer

Variable	Beta (95% CI)	p-value
Gender (male)	-0.1100 (-0.1738 to -0.04617)	0.0008
Age	-0.005231 (-0.009047 to -0.001416)	0.0073
Smoking (yes)	-0.1097 (-0.1737 to -0.04567)	0.0008
25(OH)D (Q3)	0.07601 (-0.009362 to 0.1614)	0.0809
25(OH)D (Q2)	0.1231(0.03724 to 0.2091)	0.0050
25(OH)D (Q1)	0.08248 (-0.003949 to 0.1689)	0.0614
Gender (male):age	-0.01090 (-0.01631 to -0.005490)	<0.0001

580 Adjusted R²=0.1355

581 25(OH)D quartiles: Q4; 4.1-18.89, Q3; 18.9-25.67, Q2; 25.68-32.99 Q1; 33-69.8 ng/ml

582 25(OH)D as categorical data Q1, Q2, Q3 compared to Q4 show p=0.0422

583